Modality
Peptide
MOA
PI3Ki
Target
TNFα
Pathway
Hedgehog
RABreast CaAngelman
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
Dec 2019
→ Feb 2028
Phase 1Current
NCT05636106
1,166 pts·RA
2019-12→2028-02·Recruiting
1,166 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-261.9y awayInterim· RA
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1
Recruit…
Catalysts
Interim
2028-02-26 · 1.9y away
RA
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05636106 | Phase 1 | RA | Recruiting | 1166 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα |